Avalo Therapeutics, Inc. (AVTX)

Avalo Therapeutics, Inc. (AVTX) Healthcare & Pipeline Overview

Avalo Therapeutics, Inc. is a clinical-stage precision medicine company specializing in targeted therapeutics for immunology, immuno-oncology, and rare genetic diseases. Their pipeline includes AVTX-002, an anti-LIGHT monoclonal antibody, and AVTX-801, a D-galactose substrate replacement therapy, positioning them in a competitive biotechnology landscape.

What Is the Investment Thesis for AVTX?

Avalo Therapeutics operates in the high-growth precision medicine sector, with a focus on immunology, immuno-oncology, and rare genetic diseases. Key value drivers include the successful advancement of AVTX-002 through Phase II and Phase III clinical trials, targeting multi-billion dollar markets in asthma and inflammatory bowel disease. The company's focus on rare genetic diseases, particularly AVTX-801 for PGM1-CDG, presents a significant opportunity given the limited treatment options. However, the company's negative profit margin of -132642.4% and reliance on clinical trial outcomes pose substantial risks. Successful commercialization of AVTX-801 and AVTX-803, both in Phase III trials, could drive significant revenue growth in the near term. The company's beta of 0.94 suggests moderate volatility relative to the market.

Based on FMP financials and quantitative analysis

AVTX Key Highlights

• Market capitalization of $221.48M indicates a small-cap company with potential for growth but also higher risk.
• Gross margin of 72.9% suggests strong pricing power and efficient cost management in product development.
• Profit margin of -132642.4% highlights significant losses, likely due to high R&D expenses typical of clinical-stage biotech companies.
• AVTX-002 is in Phase II clinical trial for non-eosinophilic asthma and inflammatory bowel disease, and Phase III for COVID-19 ARDS, representing near-term catalysts.
• AVTX-801 and AVTX-803 are in Phase III clinical trials for rare genetic diseases, offering potential for orphan drug designation and market exclusivity.

Who Are AVTX's Competitors?

AVTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AVTX's Key Strengths?

• Focus on precision medicine and targeted therapeutics.
• Pipeline of drug candidates in various stages of clinical development.
• Potential for orphan drug designation for rare genetic disease treatments.
• Experienced management team with expertise in drug development.

What Are AVTX's Weaknesses?

• High R&D expenses and negative profit margin.
• Reliance on clinical trial outcomes and regulatory approvals.
• Limited commercialization experience.
• Small market capitalization and potential funding challenges.

What Could Drive AVTX Stock Higher?

• Data readout from Phase II clinical trial of AVTX-002 in non-eosinophilic asthma (within 12 months).
• Data readout from Phase III clinical trials of AVTX-801 in PGM1-CDG (within 12-18 months).
• Data readout from Phase I clinical trial of AVTX-007 in Still's disease (within 12-18 months).
• Enrollment and progression of patients in ongoing clinical trials.
• Potential for strategic partnerships or collaborations to accelerate development.

What Are the Key Risks for AVTX?

• Financial-distress signal — its Altman Z-Score of -4.29 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-97.5%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or regulatory setbacks for key drug candidates.
• Competition from larger pharmaceutical companies with greater resources.
• Difficulty in securing funding to support ongoing clinical development.
• High R&D expenses and negative profit margin.
• Dependence on intellectual property protection and patent expirations.

What Are the Growth Opportunities for AVTX?

• Successful completion of Phase III trials for AVTX-801 (PGM1-CDG) represents a significant growth opportunity. PGM1-CDG is a rare genetic disorder with limited treatment options, and positive trial results could lead to orphan drug designation and market exclusivity. The market size for rare genetic diseases is substantial, with potential for high pricing and limited competition. Timeline: Anticipated data readout and potential regulatory submission within the next 12-18 months.
• Advancement of AVTX-002 in non-eosinophilic asthma and inflammatory bowel disease (IBD) offers a substantial growth opportunity. These are large and underserved markets with significant unmet needs. Positive Phase II data could attract partnerships or further investment. The asthma market is projected to reach billions of dollars in the coming years. Timeline: Phase II data expected within the next 12 months, with potential for Phase III initiation thereafter.
• Development of AVTX-007, a fully human Anti-IL-18 monoclonal antibody, for Still's disease presents a targeted growth opportunity. Still's disease is a rare systemic inflammatory disorder with limited treatment options. Positive Phase I data could pave the way for further clinical development and potential commercialization. Timeline: Ongoing Phase I trial with data expected in the next 12-18 months.
• Expansion of the pipeline through strategic acquisitions or in-licensing of promising therapeutic candidates. Avalo could leverage its expertise in precision medicine and rare genetic diseases to identify and acquire complementary assets. This could diversify the pipeline and reduce reliance on existing programs. Timeline: Ongoing, with potential for acquisitions or licensing deals in the next 12-24 months.
• Partnerships with larger pharmaceutical companies for co-development and commercialization of key assets. Avalo could leverage the resources and expertise of established players to accelerate clinical development and market access. This could provide non-dilutive funding and reduce the financial burden on the company. Timeline: Ongoing, with potential for partnership announcements in the next 12-24 months.

What Opportunities Does AVTX Have?

• Successful completion of Phase III trials and commercialization of key assets.
• Expansion of the pipeline through strategic acquisitions or in-licensing.
• Partnerships with larger pharmaceutical companies for co-development and commercialization.
• Growing demand for precision medicine and targeted therapies.

What Threats Does AVTX Face?

• Clinical trial failures and regulatory setbacks.
• Competition from larger pharmaceutical companies with greater resources.
• Patent expirations and generic competition.
• Changes in healthcare regulations and reimbursement policies.

What Are AVTX's Competitive Advantages?

• Proprietary drug candidates targeting specific diseases.
• Orphan drug designation potential for rare genetic disease treatments.
• Intellectual property protection through patents.
• Expertise in precision medicine and targeted therapeutics.

What Does AVTX Do?

Avalo Therapeutics, Inc., founded in 2011 and headquartered in Rockville, Maryland, is a clinical-stage precision medicine company dedicated to discovering, developing, and commercializing targeted therapeutics. The company focuses on addressing unmet clinical needs in immunology, immuno-oncology, and rare genetic diseases. Avalo's pipeline includes AVTX-002, a fully human anti-LIGHT monoclonal antibody currently in Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel disease, including Crohn's disease and ulcerative colitis, and in Phase III for COVID-19-related acute respiratory distress syndrome. Additionally, Avalo is developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody in Phase I clinical trials for Still's disease. Their rare genetic disease program features AVTX-801, a D-galactose substrate replacement therapy in Phase III trials for phosphoglucomutase 1 deficiency (PGM1-CDG), and AVTX-803, an L-fucose substrate replacement therapy in Phase III trials for LADII (SLC35C1-CDG). Formerly known as Cerecor Inc., the company rebranded to Avalo Therapeutics, Inc. in August 2021 to reflect its refined strategic focus on precision medicine. Avalo aims to deliver innovative therapies to patients with limited treatment options.

What Products and Services Does AVTX Offer?

• Discovers and develops targeted therapeutics for immunology.
• Creates treatments for immuno-oncology conditions.
• Develops therapies for rare genetic diseases.
• Conducts Phase II clinical trials for AVTX-002 in non-eosinophilic asthma and inflammatory bowel disease.
• Conducts Phase III clinical trials for AVTX-002 in COVID-19 acute respiratory distress syndrome.
• Develops AVTX-007, a fully human Anti-IL-18 monoclonal antibody for Still's disease.
• Develops AVTX-801, a D-galactose substrate replacement therapy for phosphoglucomutase 1 deficiency (PGM1-CDG).
• Develops AVTX-803, a L-fucose substrate replacement therapy for LADII (SLC35C1-CDG).

How Does AVTX Make Money?

• Focuses on developing and commercializing targeted therapeutics.
• Generates revenue through potential future sales of approved therapies.
• Out-licenses or partners with other companies for co-development and commercialization.
• Secures funding through venture capital, public offerings, and grants.

What Industry Does AVTX Operate In?

Avalo Therapeutics operates within the biotechnology industry, characterized by high R&D spending, lengthy clinical trials, and stringent regulatory requirements. The precision medicine segment is experiencing rapid growth, driven by advancements in genomics and personalized therapies. Competition includes both large pharmaceutical companies and smaller biotech firms focused on similar therapeutic areas. Avalo's focus on rare genetic diseases positions it in a niche market with potential for orphan drug designation and reduced competition. The overall biotechnology market is projected to continue growing, fueled by increasing healthcare expenditure and an aging population.

Who Are AVTX's Key Customers?

• Patients with immunological disorders.
• Patients with immuno-oncological conditions.
• Patients with rare genetic diseases like PGM1-CDG and LADII.
• Healthcare providers who treat these patients.

Net buyingInsider Activity

Over the past six months, Avalo Therapeutics, Inc. insiders filed 30 SEC Form 4 transactions — 14 sales and 16 purchases. On net that is roughly 304K shares acquired (about $451K) — insiders putting money in tends to read as conviction.

AVTX Valuation & Market Position

With a $221.48M market cap, Avalo Therapeutics, Inc. sits in the micro-cap segment of the market. Relative to its peer group, AVTX's quantitative score of 13/100 is below the peer average of 78/100.

ROE -98%Key Financial Metrics

Return on equity for Avalo Therapeutics, Inc. stands at -97.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -84.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -40.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.66 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -32.2%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 1/9Financial Health

Avalo Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -4.29 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Avalo Therapeutics, Inc. revenue of about $1.0M for fiscal 2026, with EPS near $-2.99. The estimate reflects 12 contributing analysts.

Company Profile

Avalo Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Rockville, US. The company is led by CEO Garry A. Neil. AVTX has traded publicly since 2015.

AVTX Financials

AVTX Latest News

AVTX Analyst Consensus

AVTX MoonshotScore

What Investors Ask About Avalo Therapeutics, Inc. (AVTX) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources